SML0116

GW788388 Hydrate

≥98% (HPLC), TGFβ signalling inhibitor, powder

• Synonym(e): 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]-pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide hydrate
• Empirische Formel (Hill-System): C₂₅H₂₃N₅O₂ · xH₂O
• Molekulargewicht: 425.48 (anhydrous basis)
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825168
• NACRES: NA.77
• MDL number: MFCD20527321
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Produktname: GW788388 Hydrate, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to tan
• solubility: DMSO: ≥8 mg/mL
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: O.O=C(NC1CCOCC1)c2ccc(cc2)-c3cc(ccn3)-c4c[nH]nc4-c5ccccn5
• InChI: 1S/C25H23N5O2.H2O/c31-25(29-20-9-13-32-14-10-20)18-6-4-17(5-7-18)23-15-19(8-12-27-23)21-16-28-30-24(21)22-3-1-2-11-26-22;/h1-8,11-12,15-16,20H,9-10,13-14H2,(H,28,30)(H,29,31);1H2
• InChI key: VZRJMBZMFKADGR-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

GW788388 is a potent selective inhibitor of TGF-beta type I receptor [activin receptor-like kinase 5 (ALK5)]. GW788388 is orally available with a half-life of approximately 4 hours.

TGFβ1 (ALK5) inhibitor; Potent, selective inhibitor of TGFβ signalling in vitro and renal fibrosis in vivo

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklasse: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• flash_point_f: Not applicable
• flash_point_c: Not applicable